Fig. 2
From: Pharmacodynamics and pharmacokinetics of a new type of recombinant insulin Lisargine injection
Curve of average exogenous insulin administration time after cross-SC Lisargine and Lantus (4 U) in 8 Beagle dogs (a). Curve of average exogenous insulin administration time after SC Lisargine (4 U and 8 U) in 8 Beagle dogs (b). The average blood glucose concentration-time curve after cross-SC Lisargine and Lantus (4 U) in 8 Beagle dogs (c). The average blood glucose concentration-time curve after SC Lisargine (4 U and 8 U) in 8 Beagle dogs (d)